Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Recurrence 1Neoplasm Metastasis 1Melanoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 22Bevacizumab 10Radiotherapy 5Magnetic Resonance Spectroscopy 5Irinotecan 5Carmustine 4fluorodopa F 18 3Topotecan 3Surgical Procedures, Operative 3Standard of Care 3Radiosurgery 3Magnetic Resonance Imaging 3Congresses as Topic 3Carboplatin 3Aminolevulinic Acid 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3ribociclib 2poly ICLC 2fluoromisonidazole 2carmustine, poliferprosan 20 drug combination 2cabozantinib 2Vorinostat 2TIC10 compound 2Re-Irradiation 2Radiotherapy, Intensity-Modulated 2Panobinostat 2O(6)-benzylguanine 2Melphalan 2Lomustine 2Lacosamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Glioma × Maintenance × Clear all
NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Regeneron Pharmaceuticals

Phase 1/2 Terminated
57 enrolled 31 charts
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡